HomeCompareTCCR vs ABBV

TCCR vs ABBV: Dividend Comparison 2026

TCCR yields 133.33% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCCR wins by $13.86M in total portfolio value
10 years
TCCR
TCCR
● Live price
133.33%
Share price
$1.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13.97M
Annual income
$5,641,791.08
Full TCCR calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TCCR vs ABBV

📍 TCCR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCCRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCCR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCCR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCCR
Annual income on $10K today (after 15% tax)
$11,333.33/yr
After 10yr DRIP, annual income (after tax)
$4,795,522.42/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TCCR beats the other by $4,774,466.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCCR + ABBV for your $10,000?

TCCR: 50%ABBV: 50%
100% ABBV50/50100% TCCR
Portfolio after 10yr
$7.03M
Annual income
$2,833,281.42/yr
Blended yield
40.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TCCR
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCCR buys
0
ABBV buys
0
No recent congressional trades found for TCCR or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCCRABBV
Forward yield133.33%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$13.97M$102.3K
Annual income after 10y$5,641,791.08$24,771.77
Total dividends collected$12.81M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TCCR vs ABBV ($10,000, DRIP)

YearTCCR PortfolioTCCR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$24,033$13,333.33$11,550$430.00+$12.5KTCCR
2$55,664$29,948.08$13,472$627.96+$42.2KTCCR
3$124,385$64,825.16$15,906$926.08+$108.5KTCCR
4$268,473$135,380.68$19,071$1,382.55+$249.4KTCCR
5$560,355$273,089.05$23,302$2,095.81+$537.1KTCCR
6$1,132,281$532,700.68$29,150$3,237.93+$1.10MTCCR
7$2,217,522$1,005,981.95$37,536$5,121.41+$2.18MTCCR
8$4,214,031$1,841,281.95$50,079$8,338.38+$4.16MTCCR
9$7,779,152$3,270,139.09$69,753$14,065.80+$7.71MTCCR
10$13,965,484$5,641,791.08$102,337$24,771.77+$13.86MTCCR

TCCR vs ABBV: Complete Analysis 2026

TCCRStock

TRICCAR, Inc. provides saltwater disposal services. The company offers its services to oil and gas operators that produce hydrocarbons to dispose of their by-product of saltwater. It operates saltwater disposal wells located in Wise County, Texas. The company is based in Shreveport, Louisiana.

Full TCCR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TCCR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCCR vs SCHDTCCR vs JEPITCCR vs OTCCR vs KOTCCR vs MAINTCCR vs JNJTCCR vs MRKTCCR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.